Abstract
The efficacy and safety of the peripheral kappa agonist fedotozine was evaluated in a double-blind, multicenter study involving 238 patients with the irritable bowel syndrome. After a two-week washout, patients were assigned to one of four groups to receive either placebo or fedotozine three times a day at doses of 3.5, 15, or 30 mg for six weeks. Patient assessment of mean symptom intensity indicated that the 30-mg dose of fedotozine was superior to placebo in relieving maximal daily abdominal pain (P=0.01), mean daily pain (P=0.007), and abdominal bloating (P=0.02). Changes in bowel function and defecation disorders could not be evaluated reliably. According to the investigators, the highest dose of fedotozine markedly reduced overall disease severity (P=0.003) and the pain component of the symptomatic profile (P=0.009). Clinical and laboratory safety was very good. Fedotozine 30 mg three times a day therefore appears to be effective and safe in the treatment of the abdominal pain and bloating associated with IBS.
Similar content being viewed by others
References
Bommelaer G, Rouch M, Dapoigny M, Pais D, Loisy P, Gualino M, Tournut R. Epidémiologie des troubles fonctionnels intestinaux dans une population apparemment saine. Gastroenterol Clin Biol 10:7–12, 1986
Buéno L, Fioramonti J, Ruckebusch Y, Frexinos J, Colom P. Evaluation of colonic myoelectrical activity in health and functional disorders. Gut 21:480–485, 1980
Kellow JE, Phillips SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 92:1885–1893, 1987
Lind CD: Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 20:279–295, 1991
Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14:125–132, 1973
Read NW: Irritable bowel syndrome (IBS)—definition and pathophysiology. Scand J Gastroenterol Suppl 130:7–13, 1987
Wingate DL: The irritable bowel syndrome. Gastroenterol Clin North Am 20:351–362, 1991
Diop L, Rivière P, Pascaud X, Junien JL: Peripheral kappa opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur J Pharmacol 271:65–71, 1994
Rivière PJM, Pascaud X, Chevalier E, Le Gallou B, Junien JL: Fedotozine reverses ileus induced by surgery or peritonitis: Action at peripheral kappa opioid receptors. Gastroenterology 104:724–731, 1993
Rivière PJM, Pascaud X, Chevalier E, Junien JL: Fedotozine reversal of peritoneal irritation-induced ileus in rats: Possible peripheral action on sensory afferents. J Pharmacol Exp Ther 270:846–850, 1994
Gué M, Junien JL, Pascaud X, Bueno L: Antagonism of stress-induced motor alteration and plasma cortisol release by fedotozine (JO 1196) in dogs. J Gastrointest Motil 2:258–264, 1990
Gué M, Junien JL, Buéno L: The kappa agonist fedotozine modulates colonic distension-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 107:1327–1334, 1994
Coffin B, Jian R, Lémann M, Fraitag B, Van Egroo LD, Franchisseur C, Rambauc JC: Fedotozine increases threshold of discomfort to gastric distension in healthy subjects. Gastroenterology 102:A437, 1992 (abstract)
Fraitag B, Homerin M, Hecketsweiler P: Double-blind doseresponse multicenter comparison of fedotozine and placebo in the treatment of nonulcer dyspepsia. Dig Dis Sci 39:1072–1077, 1994
Talley NJ, Piper DW: The association between nonulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 20:896–900, 1985
Kirk RE: Experimental Design: Procedures for the Behavioral Sciences. 2nd ed. Pacific Grove, California, Brooks/Cole Publishing, 1982
Pattee PL, Thompson WG: Drug treatment of the irritable bowel syndrome. Drugs 44:200–206, 1992
Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ: Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters. Gastroenterology 102:1962–1967, 1992
Manning AP, Thompson WG, Heaton KW, Lorris AF: Towards positive diagnosis of the irritable bowel. Br Med J 2:653–654, 1978
Talley NJ, Nyren O, Drossman DA, Heaton KW, Veldhuyzen van Zanten SJO, Koch MM, Ransohoff DF: The irritable bowel syndrome: Toward optimal design of controlled treatment trials. Gastroenterol Int 6:189–211, 1993
Author information
Authors and Affiliations
Additional information
Participating investigators: [France] Bataillon, Beaujard, Beranger, Boisson. Boboc, Bour, Bourry, Boyer, Cambon, Cassan, Chambon, Chery, Cosmidis, Dahlab, Dapoigny, Daudet, Debat, Delette. Delvaux, Desechalliers, Diez, Dumas, Faucher, Girard, Gislon, Hamelin, Hayek. Hecketsweiler, Joliot, Kornhauser, Lafon, Lamouliatte, Larche, Le Bihan, Legoux, Lirzin. Ljunggren, Marcheta, Marquier, Milon, Molinie, Monneris, Montoya, Morichau-Beauchant, Naudy, Pillegand, Raud Regeard, Renson, Richieri, Rouison, Rumeau, Salas, Staub, Vandermolen, Verbiese, Veyres, Wagner, Weber, Yousfi, Zani: [Tunisia] Ben Amar, Ben Kahlifa, Garoui, Hamza: [Belgium] Lamy, Lienard, Peeters.
Rights and permissions
About this article
Cite this article
Dapoigny, M., Abitbol, J.L. & Fraitag, B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Digest Dis Sci 40, 2244–2249 (1995). https://doi.org/10.1007/BF02209014
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02209014